Pinnacle Medicines raised $89 million in an oversubscribed Series B financing round on March 26, 2026, bringing total funding to $134 million.123
The round was co-led by LAV and Foresite Capital, with participation from OrbiMed, Quan Capital, Hankang Capital, RA Capital Management, and Logos Capital.134
Funds will advance preclinical oral peptide programs into early clinical testing, focusing on immunology and cardiometabolic indications.136
Pinnacle uses a proprietary platform integrating AI, physics-based simulations, and advanced peptide chemistry to develop oral therapeutics.36
Company founded in 2024, based in Doylestown, PA and China.134
Sources:
1. https://www.fiercebiotech.com/biotech/orbimed-backed-pinnacle-adds-89m-series-b-power-oral-peptide-pipeline
2. https://www.bioworld.com/articles/729903-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs
3. https://vcnewsdaily.com/pinnacle-medicines/venture-capital-funding/jhjvmzmmjj
4. https://letsdatascience.com/news/pinnacle-medicines-raises-89m-series-b-e1ccbc3d
6. https://www.biotechsnap.com/p/pinnacle-raises-89m-for-its-oral-peptide-drugs-beam-reports-positive-phase-1-2-trial-of-its-base-edi